Skip to content
Gossamer Bio
-
Gossamer Bio secures US$250M to advance seralutinib toward FDA review
Seralutinib is an investigational treatment for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).